BR112017006272A2 - composição farmacêutica para tratar colite ulcerativa. - Google Patents

composição farmacêutica para tratar colite ulcerativa.

Info

Publication number
BR112017006272A2
BR112017006272A2 BR112017006272-0A BR112017006272A BR112017006272A2 BR 112017006272 A2 BR112017006272 A2 BR 112017006272A2 BR 112017006272 A BR112017006272 A BR 112017006272A BR 112017006272 A2 BR112017006272 A2 BR 112017006272A2
Authority
BR
Brazil
Prior art keywords
ulcerative colitis
medical treatment
chronic ulcerative
medicine constituent
constituent
Prior art date
Application number
BR112017006272-0A
Other languages
English (en)
Japanese (ja)
Inventor
Kageyama Shunsuke
Goda Yoshiki
Sugiura Toshihiko
Original Assignee
Ea Pharma Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ea Pharma Co., Ltd. filed Critical Ea Pharma Co., Ltd.
Publication of BR112017006272A2 publication Critical patent/BR112017006272A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

é provida uma composição farmacêutica que é para tratar colite ulcerativa e inclui um composto representado pela fórmula (1) ou um sal farmaceuticamente aceitável do mesmo, em que o dito composto ou sal farmaceuticamente aceitável do mesmo é administrado a um paciente tendo colite ulcerativa em uma dose de pelo menos 600 mg por dia.
BR112017006272-0A 2014-09-29 2015-03-27 composição farmacêutica para tratar colite ulcerativa. BR112017006272A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014-198681 2014-09-29
JP2014198681 2014-09-29
PCT/JP2015/059717 WO2016051828A1 (ja) 2014-09-29 2015-03-27 潰瘍性大腸炎の治療用医薬組成物

Publications (1)

Publication Number Publication Date
BR112017006272A2 true BR112017006272A2 (pt) 2018-03-13

Family

ID=55629887

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017006272-0A BR112017006272A2 (pt) 2014-09-29 2015-03-27 composição farmacêutica para tratar colite ulcerativa.

Country Status (9)

Country Link
US (1) US10183022B2 (pt)
JP (1) JP6580053B2 (pt)
KR (1) KR102319078B1 (pt)
AU (1) AU2015326196B2 (pt)
BR (1) BR112017006272A2 (pt)
CA (1) CA2961311C (pt)
EA (1) EA034956B1 (pt)
MX (1) MX2017003780A (pt)
WO (1) WO2016051828A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3514235B8 (de) * 2018-01-18 2024-02-14 Sterna Biologicals GmbH Zusammensetzung zur behandlung eines an colitis ulcerosa leidenden patienten sowie verwendung der zusammensetzung als arzneimittel
CN112969687A (zh) 2018-10-30 2021-06-15 吉利德科学公司 作为α4β7整合素抑制剂的喹啉衍生物
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
CA3115830C (en) 2018-10-30 2023-09-12 Gilead Sciences, Inc. Compounds for inhibition of .alpha.4.beta.7 integrin
KR102641718B1 (ko) 2018-10-30 2024-02-29 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 이미다조피리딘 유도체
CN114222730A (zh) 2019-08-14 2022-03-22 吉利德科学公司 用于抑制α4β7整合素的化合物
GB202002926D0 (en) * 2020-02-28 2020-04-15 Benevolentai Tech Limited Compositions and uses thereof
KR20230066169A (ko) 2021-11-05 2023-05-15 (주) 넥셀 궤양성 대장염 예방 또는 치료용 재조합 단백질 및 이를 포함하는 궤양성 대장염 예방 또는 치료용 조성물
CN114668775B (zh) * 2022-02-28 2023-12-19 中国药科大学 纤维素衍生物在制备治疗溃疡性结肠炎药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3440469B2 (ja) 2000-08-18 2003-08-25 味の素株式会社 新規フェニルアラニン誘導体
EP1595870B1 (en) 2003-02-20 2015-09-23 Ajinomoto Co., Inc. Process for producing phenylalanine derivative having quinazolinedione skeleton and intermediate for the same
EP3216449A1 (en) 2003-11-14 2017-09-13 EA Pharma Co., Ltd. Oral administration preparation of phenylalanine derivatives
DK1683524T3 (da) 2003-11-14 2011-03-14 Ajinomoto Kk Dispergering på fast form eller medicinsk præparat på fast form af phenyalaninderivat
WO2005051525A1 (en) 2003-11-25 2005-06-09 Polyvalor, Limited Partnership Permeation barrier coating or layer with modulated properties and methods of making the same
CA2547625C (en) 2003-11-27 2012-07-24 Ajinomoto Co., Inc. Crystals of phenylalanine derivatives and production methods thereof
EP1916241B1 (en) 2005-06-21 2013-06-12 Ajinomoto Co., Inc. Crystal of phenylalanine derivative, process for producing the same and use thereof
CN101589028B (zh) 2006-11-22 2014-02-19 味之素株式会社 具有喹唑啉二酮骨架的苯丙氨酸衍生物的制备方法及制备中间体
US7987289B2 (en) 2008-06-24 2011-07-26 Microsoft Corporation Participating in cloud as totally stubby edge
EP2993173A1 (en) * 2010-03-29 2016-03-09 Ajinomoto Co., Inc. Crystals of salts of phenylalanine derivatives
ES2768349T3 (es) 2010-03-29 2020-06-22 Ea Pharma Co Ltd Preparación farmacéutica que comprende un derivado de fenilalanina

Also Published As

Publication number Publication date
EA034956B1 (ru) 2020-04-10
WO2016051828A1 (ja) 2016-04-07
KR102319078B1 (ko) 2021-10-29
US20170196870A1 (en) 2017-07-13
MX2017003780A (es) 2017-06-30
JP6580053B2 (ja) 2019-09-25
AU2015326196A1 (en) 2017-03-23
CA2961311A1 (en) 2016-04-07
KR20170057435A (ko) 2017-05-24
CA2961311C (en) 2022-12-06
EA201790726A1 (ru) 2017-11-30
AU2015326196B2 (en) 2020-05-14
JPWO2016051828A1 (ja) 2017-07-27
US10183022B2 (en) 2019-01-22

Similar Documents

Publication Publication Date Title
BR112017006272A2 (pt) composição farmacêutica para tratar colite ulcerativa.
EA201690069A1 (ru) Применение высоких доз придопидина для лечения болезни хантингтона
BR112017010551A2 (pt) composto, métodos para ativação de guanilato ciclase solúvel, para tratamento de uma ou mais condições selecionadas a partir de uma doença em um paciente e para tratamento de uma doença ou condição, composição farmacêutica, uso de um composto, e, medicamento.
BR112016027041A8 (pt) combinações farmacêuticas para tratamento do câncer
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
BR112017007144A2 (pt) ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição.
PH12016502352A1 (en) Pharmaceutical composition
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
TW201613578A (en) Pharmaceutical combinations
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
BR112016027435A2 (pt) formulação inovadora de meloxicam
BR112019005456A2 (pt) composição farmacêutica e método para tratamento de esteatose hepática não alcoólica
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
MX2017015664A (es) Administracion intravenosa de citrulina durante cirugia.
AR102308A1 (es) Composición farmacéutica para usar en el tratamiento o prevención de deficiencias de vitaminas y minerales en pacientes sometidos a cirugía de bypass gástrico
BR112014030288A8 (pt) composição farmacêutica, uso da mesma, e, uso de metanossulfonilacetonitrila
BR112017002449A2 (pt) tratamento de sintomas associados com terapia de privação androgênica
BR112018068784A2 (pt) método para o tratamento de leucemia
BR112018068910A2 (pt) sultiame para o tratamento de apneia do sono
MX2018011293A (es) Composicion farmaceutica de liberacion prolongada que comprende cisteamina o sal de la misma.
PH12016501026A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
MX2018005298A (es) Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
PH12016502107A1 (en) Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
MD4458B1 (ro) Utilizarea preparatului Polibiolină în tratamentul bolnavilor cu ciroză hepatică
UA105586U (uk) Спосіб лікування печінкової енцефалопатії

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]